I specialize in the care of patients with urologic cancers – mainly prostate cancer, kidney cancer, bladder cancer and testicular cancer. A cancer diagnosis is one of the scariest things that can happen to someone. For many of our patients, they don’t necessarily feel different or look different, but they are scared to death. The most important thing you can get from Duke is real understanding of your particular case and what your options are. Knowledge is so reassuring and empowering for patients, especially those recently diagnosed with cancer. When you’re first diagnosed, you have to put your trust in a care team, and that’s hard to do if you don’t already know them. As the largest cancer center in North Carolina, Duke has great reputation and experience, which helps many patients chose Duke for their care. But we grow and develop our trust with patients because of who we are as people and how much expertise and care we bring to each case. Dr. George is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Endoscopy.

Sumanta Pal is an Oncologist in Newport Beach, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Heather Wakelee is an Oncologist in Stanford, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.

Anne Tsao is an Oncologist and a Hematologist in Houston, Texas. Dr. Tsao is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, and Tissue Biopsy.

Hossein Borghaei is an Oncologist and a Radiologist in Philadelphia, Pennsylvania. Dr. Borghaei is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Tanya Dorff is an Oncologist and a Hematologist Oncology provider in South Pasadena, California. Dr. Dorff is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Prostate Cancer, Penile Cancer, Familial Prostate Cancer, Prostatectomy, and Penectomy.

Vamsidhar Velcheti is a Hematologist Oncology specialist and an Oncologist in Jacksonville, Florida. Dr. Velcheti is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Rana Mckay is a Hematologist Oncology specialist and a Hematologist in San Diego, California. Dr. Mckay is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Marianna Koczywas is an Oncologist in Duarte, California. Dr. Koczywas is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Christopher Azzoli is an Oncologist and a Hematologist in Providence, Rhode Island. Dr. Azzoli is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

Anil Sood is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Sood is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Endoscopy, and Oophorectomy.

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Charu Aggarwal is an Oncologist in Philadelphia, Pennsylvania. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is currently accepting new patients.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Mehmet Bilen is an Oncologist in Atlanta, Georgia. Dr. Bilen has been practicing medicine for over 18 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy.

Joyce O'shaughnessy is an Oncologist and an Internal Medicine provider in Dallas, Texas. Dr. O'shaughnessy has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, HER2 Negative Breast Cancer, and Tissue Biopsy.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center. Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute. Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy.